Design Therapeutics, Inc.
DSGN
$10.30
-$0.74-6.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.32% | 33.92% | 23.69% | 39.89% | 6.56% |
| Gross Profit | -33.32% | -33.92% | -23.69% | -39.89% | -6.56% |
| SG&A Expenses | 12.78% | 14.35% | 5.21% | -6.72% | -14.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.39% | 28.26% | 18.21% | -3.58% | -20.22% |
| Operating Income | -27.39% | -28.26% | -18.21% | 3.58% | 20.22% |
| Income Before Tax | -40.74% | -41.16% | -25.65% | 4.22% | 25.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.74% | -41.16% | -25.65% | 4.22% | 25.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.74% | -41.16% | -25.65% | 4.22% | 25.84% |
| EBIT | -27.39% | -28.26% | -18.21% | 3.58% | 20.22% |
| EBITDA | -27.61% | -28.48% | -18.30% | 3.69% | 20.43% |
| EPS Basic | -39.07% | -40.21% | -24.56% | 5.19% | 26.65% |
| Normalized Basic EPS | -39.08% | -40.22% | -24.54% | 5.21% | 26.66% |
| EPS Diluted | -39.07% | -40.21% | -24.56% | 5.19% | 26.65% |
| Normalized Diluted EPS | -39.08% | -40.22% | -24.54% | 5.21% | 26.66% |
| Average Basic Shares Outstanding | 1.31% | 0.66% | 0.80% | 0.94% | 1.08% |
| Average Diluted Shares Outstanding | 1.31% | 0.66% | 0.80% | 0.94% | 1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |